Showing 1091-1100 of 21419 results for "".
- IgA Nephropathy Linked to Cardiometabolic Genetic Overlaphttps://reachmd.com/news/iga-nephropathy-cardiometabolic-genetic-overlap/2488265/Key Takeaways An integrative genomic analysis of IgA nephropathy and related vascular, metabolic, and immune traits reported significant shared inherited susceptibility across multiple vascular and metabolic phenotypes. Risk-factor phenotypes showed stronger overlap
- ICU Pain Was Common and Persistent in a 711-Patient Cohorthttps://reachmd.com/news/icu-pain-was-common-and-persistent-in-a-711-patient-cohort/2488242/Key Takeaways Among mixed adult ICU patients in four ICUs across two tertiary university hospitals in Finland, pain at rest was commonly documented during ICU stay. Average daily pain prevalence was 43.7%, and the burden did not decline during follow-up. Fem
- Cuttlefish Ink-Derived Microneedles Show Potential for Vitiligo Repigmentationhttps://reachmd.com/news/cuttlefish-ink-derived-microneedles-show-potential-for-vitiligo-repigmentation/2488260/Researchers have developed a fast-dissolving microneedle platform designed to address oxidative stress, inflammation, melanocyte loss, and depigmentation in vitiligo, according to a preclinical study published in Marine Life Scie
- Vision Loss After Nonsurgical Rhinoplasty Often Immediate: Systematic Reviewhttps://reachmd.com/news/vision-loss-after-nonsurgical-rhinoplasty-often-immediate-systematic-review/2488257/Vision loss following nonsurgical rhinoplasty with dermal fillers is rare but can result in persistent visual impairment, according to findings from a systematic review of published cases. Vision Los
- Maternal and Infant Skin Microbiomes Show Distinct but Connected Developmenthttps://reachmd.com/news/maternal-and-infant-skin-microbiomes-show-distinct-but-connected-development/2488255/The skin microbiomes of mothers and their infants appear to be closely connected during early life, although infant microbial diversity follows its own developmental trajectory, according to a recent longitudinal study published in Experimental Dermatology. Researchers for the stu
- Brepocitinib Associated with Improved Skin Outcomes in Dermatomyositishttps://reachmd.com/news/brepocitinib-skin-outcomes-dermatomyositis/2488232/Key Takeaways In adults with dermatomyositis in the phase 3 VALOR trial, brepocitinib 30 mg was associated with better skin-specific outcomes than placebo. Improvement in cutaneous disease activity was seen by week 4 and was reported through week 52 with brepocitinib
- Asthma in Pregnancy: ICS Continuation Not Linked to Higher Riskhttps://reachmd.com/news/asthma-in-pregnancy-ics-continuation-not-linked-to-higher-risk/2488210/Key Takeaways In women in Korea with asthma who had used ICS before pregnancy, first-trimester continuation and discontinuation were the exposure patterns compared in a nationwide live-birth cohort. First-trimester ICS discontinuation was more common than continuatio
- Acetaminophen Tops Poison Center Liver Injury Reportshttps://reachmd.com/news/acetaminophen-tops-poison-center-liver-injury-reports/2488223/Key Takeaways Across U.S. poison-center surveillance, reported xenobiotic-associated liver injury increased over time, and most cases required inpatient care. Acetaminophen was the most frequently implicated substance in reported U.S. poison-center liver injury cases
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://reachmd.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Early Infections Linked to Childhood Atopic Dermatitis Riskhttps://reachmd.com/news/early-infections-linked-to-childhood-atopic-dermatitis-risk/2488211/Key Takeaways Children in Danish and U.S. birth cohorts with higher early infection burden from ages 0 to 3 years had higher odds of childhood AD. AD odds increased as infection episodes and infection days accumulated, consistent with a dose-response pattern.